From the Editors

The February issue of The Oncology Pharmacist (TOP) features presentations and studies from national and international meetings, including the 2018 Palliative and Supportive Care in Oncology Symposium, the European Society for Medical Oncology (ESMO) 2018 Congress, and the 2018 International Association for the Study of Lung Cancer World Conference on Lung Cancer.

From the Editor - TOP November 2018

The November issue of The Oncology Pharmacist (TOP) features key presentations from the Hematology/Oncology Pharmacy Association 2018 Practice Management Conference.

From the Editor - TOP August 2018

In the August issue of The Oncology Pharmacist (TOP), we feature results of a clinical trial presented at the 2018 American Association for Cancer Research meeting, which showed that the addition of the immune checkpoint inhibitor pembrolizumab to chemotherapy yielded significantly longer overall survival and progression-free survival compared with chemotherapy alone in patients with newly diagnosed metastatic nonsquamous non–small-cell lung cancer.

From The Editors - TOP November 2017

Results from another clinical trial, ALEX, were also presented at the meeting, and led to alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, being hailed as a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer.

From the Editors

Here's what you can expect to find in the August issue of The Oncology Pharmacist.

From the Editors

In the May issue of The Oncology Pharmacist (TOP), we feature a conversation with Patrick J. Medina, PharmD, BCOP, Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa, in which he discusses changes to the reimbursement model, bridging the knowledge gap in a rapidly evolving field, and why provider status is the “holy grail” of pharmacy.

From the Editors

Here's what to expect from the February issue of The Oncology Pharmacist.

From the Editors

In the October issue of The Oncology Pharmacist, we feature highlights from the recent Hematology/Oncology Pharmacy Association (HOPA)’s Oncology Pharmacy Practice Management Program, including an article on the challenges of managing patients with non–small-cell lung cancer (NSCLC) associated with ALK mutations. At HOPA, Jim M. Koeller, MS, Professor, College of Pharmacy, The University of Texas at Austin, discussed the current treatment guidelines for this patient population, emphasizing the need for pharmacist inclusion during testing for ALK mutations.

From the Editors

In this issue of The Oncology Pharmacist, we feature an article on the new—and often misunderstood—world of biosimilars

From the Editors

In the May issue of The Oncology Pharmacist, we feature a recent study that was presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium on the association between prophylactic gabapentin, weight loss, and narcotic dependency in patients with oropharyngeal cancer undergoing radiation therapy.

Page 2 of 4
Results 11 - 20 of 33